Enzo Biochem (ENZ) Competitors

Enzo Biochem (NYSE:ENZ) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Does the MarketBeat Community prefer ENZ or PIII?

Enzo Biochem received 207 more outperform votes than P3 Health Partners when rated by MarketBeat users. Likewise, 52.48% of users gave Enzo Biochem an outperform vote while only 31.25% of users gave P3 Health Partners an outperform vote.

Company	Underperform	Outperform
Enzo Biochem	Outperform Votes 212 52.48%	Underperform Votes 192 47.52%
P3 Health Partners	Outperform Votes 5 31.25%	Underperform Votes 11 68.75%

Do analysts prefer ENZ or PIII?

P3 Health Partners has a consensus price target of $16.25, indicating a potential upside of 84.66%. Given P3 Health Partners' stronger consensus rating and higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Enzo Biochem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enzo Biochem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
P3 Health Partners	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has more volatility and risk, ENZ or PIII?

Enzo Biochem has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Do institutionals and insiders believe in ENZ or PIII?

36.9% of Enzo Biochem shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 11.4% of Enzo Biochem shares are held by company insiders. Comparatively, 15.8% of P3 Health Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has higher valuation and earnings, ENZ or PIII?

Enzo Biochem has higher earnings, but lower revenue than P3 Health Partners.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enzo Biochem	$29.09M	0.59	-$26.08M	N/A	N/A
P3 Health Partners	$1.50B	0.04	-$57.77M	-$49.00	-0.18

Is ENZ or PIII more profitable?

P3 Health Partners has a net margin of -6.95% compared to Enzo Biochem's net margin of -75.34%. Enzo Biochem's return on equity of -7.96% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enzo Biochem	-75.34%	-7.96%	-5.49%
P3 Health Partners	-6.95%	-71.31%	-11.93%

Does the media refer more to ENZ or PIII?

In the previous week, P3 Health Partners had 1 more articles in the media than Enzo Biochem. MarketBeat recorded 1 mentions for P3 Health Partners and 0 mentions for Enzo Biochem. P3 Health Partners' average media sentiment score of 1.44 beat Enzo Biochem's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Enzo Biochem	Neutral
P3 Health Partners	Positive

Summary

Enzo Biochem and P3 Health Partners tied by winning 8 of the 16 factors compared between the two stocks.